773 related articles for article (PubMed ID: 33933537)
1. Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.
Röpke J; Ferreira-Vieira TH; Iglesias LP; Asth L; Ribeiro FM; Moreira FA
Pharmacol Biochem Behav; 2021 Jul; 206():173193. PubMed ID: 33933537
[TBL] [Abstract][Full Text] [Related]
2. Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Röpke J; Busanello A; Leal CQ; de Moraes Reis E; de Freitas CM; Villarinho JG; Figueira FH; Mello CF; Ferreira J; Fachinetto R
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():195-9. PubMed ID: 24747871
[TBL] [Abstract][Full Text] [Related]
3. Anticonvulsive effects of endocannabinoids; an investigation to determine the role of regulatory components of endocannabinoid metabolism in the Pentylenetetrazol induced tonic- clonic seizures.
Zareie P; Sadegh M; Palizvan MR; Moradi-Chameh H
Metab Brain Dis; 2018 Jun; 33(3):939-948. PubMed ID: 29504066
[TBL] [Abstract][Full Text] [Related]
4. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Medeiros P; de Freitas RL; Silva MO; Coimbra NC; Melo-Thomas L
Neuroscience; 2016 Nov; 337():17-26. PubMed ID: 27595886
[TBL] [Abstract][Full Text] [Related]
5. Activation of CB
Karpińska O; Baranowska-Kuczko M; Kloza M; Ambroz Ewicz E; Kozłowski T; Kasacka I; Malinowska B; Kozłowska H
Am J Physiol Regul Integr Comp Physiol; 2017 Jun; 312(6):R883-R893. PubMed ID: 28356298
[TBL] [Abstract][Full Text] [Related]
6. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
7. N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus.
Gobira PH; Lima IV; Batista LA; de Oliveira AC; Resstel LB; Wotjak CT; Aguiar DC; Moreira FA
J Psychopharmacol; 2017 Jun; 31(6):750-756. PubMed ID: 28583049
[TBL] [Abstract][Full Text] [Related]
8. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
10. Opposing roles of CB
Gobira PH; Oliveira AC; Gomes JS; da Silveira VT; Asth L; Bastos JR; Batista EM; Issy AC; Okine BN; de Oliveira AC; Ribeiro FM; Del Bel EA; Aguiar DC; Finn DP; Moreira FA
Br J Pharmacol; 2019 May; 176(10):1541-1551. PubMed ID: 30101419
[TBL] [Abstract][Full Text] [Related]
11. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Naidu PS; Kulkarni SK
Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
[TBL] [Abstract][Full Text] [Related]
12. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Shi J; Tan YL; Wang ZR; An HM; Li J; Wang YC; Lv MH; Yan SX; Wu JQ; Soares JC; Yang FD; Zhang XY
Pharmacol Biochem Behav; 2016 Sep; 148():53-8. PubMed ID: 27264436
[TBL] [Abstract][Full Text] [Related]
13. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
14. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons.
Llorente-Berzal A; Terzian AL; di Marzo V; Micale V; Viveros MP; Wotjak CT
Psychopharmacology (Berl); 2015 Aug; 232(15):2811-25. PubMed ID: 25814137
[TBL] [Abstract][Full Text] [Related]
15. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats.
Rivera P; Luque-Rojas MJ; Pastor A; Blanco E; Pavón FJ; Serrano A; Crespillo A; Vida M; Grondona JM; Cifuentes M; Bermúdez-Silva FJ; de la Torre R; de Fonseca FR; Suárez J
Eur J Neurosci; 2013 Jan; 37(1):105-17. PubMed ID: 23033907
[TBL] [Abstract][Full Text] [Related]
16. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Bordia T; Zhang D; Perez XA; Quik M
Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol.
Kajero JA; Seedat S; Ohaeri J; Akindele A; Aina O
World J Biol Psychiatry; 2020 Oct; 21(8):612-626. PubMed ID: 32264772
[No Abstract] [Full Text] [Related]
18. Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats.
Hartmann A; Fassini A; Scopinho A; Correa FM; Guimarães FS; Lisboa SF; Resstel LB
J Psychopharmacol; 2019 May; 33(5):606-614. PubMed ID: 30789299
[TBL] [Abstract][Full Text] [Related]
19. PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
Sonego AB; Prado DDS; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110367. PubMed ID: 34048863
[TBL] [Abstract][Full Text] [Related]
20. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
